Business Overview / Sources of Revenue

Alnylam Pharmaceuticals is a **biopharmaceutical company specializing in RNAi (RNA interference) therapeutics** for rare genetic and orphan diseases.[2]

The company generates revenue primarily through four commercial products:[2][3]

**TTR Amyloidosis Franchise (dominant revenue source):**
- **AMVUTTRA** and **ONPATTRO** treat transthyretin (TTR) amyloidosis, contributing $2.49 billion in 2025 revenues (103% growth year-over-year)[5]
- Projected to generate $4.4–$4.7 billion in 2026[3]

**Rare Disease Portfolio:**
- **GIVLAARI** (givosiran) and **OXLUMO** (lumasiran) for other rare metabolic disorders
- Combined 2025 revenues: $499 million with 18% growth[3]
- Projected $500–$600 million in 2026[3]

**Overall Performance:**
Total 2025 net product revenues reached $2.99 billion (81% growth), with the TTR franchise representing approximately 83% of total revenue.[2][3] Under its "Alnylam 2030" strategy, the company projects 2026 combined revenues of $4.9–$5.3 billion while investing ~30% of revenues in R&D.[2]

Revenue Growth Potential and Recurrence

**Alnylam Pharmaceuticals (ALNY) has a large share of recurring revenue from net product sales**, which comprised the majority of total revenues (e.g., $851M of $1,249M in Q3 2025, up 103% YoY; $672M of $774M in Q2 2025, up 64% YoY).[1][4][6] These stem from chronic therapies like AMVUTTRA (TTR franchise), GIVLAARI, and OXLUMO, with consistent patient-driven growth offsetting ONPATTRO switches.[1][2][3][4]

**Revenue growth potential over 5+ years appears strong**, fueled by TTR (e.g., 135% YoY in Q3 2025) and Rare disease franchises (14-34% YoY), plus Roche collaborations and royalties (up 98%).[1][2][3][4] Guidance implies 25-39% net product growth; pipeline (e.g., fitusiran royalties) supports sustained expansion, though no precise 5-year rates are specified.[2][3][8] (98 words)

Economic Moat Factors

Alnylam Pharmaceuticals possesses a **narrow economic moat** built on several competitive advantages[6]. The company's **extensive patent portfolio and strategic licensing agreements** provide intellectual property protection, safeguarding innovations in RNAi technology[1]. Its **unique assets** include proprietary siRNA platform capabilities that create barriers to entry in this specialized field.

**Switching costs** emerge as patients and physicians invest in Alnylam's approved therapies like AMVUTTRA, creating some lock-in effects[3]. The company benefits from **brand power** through pioneering RNAi commercialization and strategic partnerships with industry leaders like Sanofi and Regeneron, expanding market reach[1][2].

However, the moat appears limited by competitive pressures in biotechnology and high R&D costs. While Alnylam demonstrates strong revenue growth—103% in Q3 2025—this reflects market expansion rather than entrenched competitive advantages[3]. The company's pipeline progress and diversified product portfolio provide some protection, but the moat lacks the durability of established pharmaceutical giants with broader therapeutic portfolios and global distribution networks.

Leadership

**Yvonne Greenstreet** has been CEO of Alnylam Pharmaceuticals (ALNY) since January 1, 2022, succeeding **John Maraganore**, who served as founding CEO from 2002-2021 but is not a founder.[1][5][6] Greenstreet, former president and COO, leads the RNAi therapeutics pioneer with approved drugs like ONPATTRO.[5][7] No specific ownership stakes for Greenstreet are detailed in available data. Management built Alnylam from a startup to multiple FDA approvals under Maraganore's 19-year tenure.[1][4][6] (78 words)

Financial Health

Alnylam Pharmaceuticals (ALNY) has a **moderately healthy balance sheet** with **$2.7-2.86B cash** slightly exceeding **$2.5-2.77B debt** (net cash ~$118M), but a high **debt-to-equity ratio of 10.93-1071%** signals leverage risk despite strong liquidity (current ratio 2.54-2.80).[1][2][3]

It generates **positive free cash flow** ($1.57B TTM, $17.80/share), though margin data is unavailable; operating cash flow recently turned positive.[1][4][7]

The company has been **dilutive**, issuing shares/debt for growth rather than repurchasing.[4] (78 words)

Last updated Jan 31, 2026